MK-8507 in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)
Status:
Not yet recruiting
Trial end date:
2022-05-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate pharmacokinetics (PK) and safety of a single oral
dose of MK-8507 in participants with mild or moderate hepatic impairment (HI). It is
hypothesized that the area under the plasma concentration-time curve from dosing to
(extrapolated) infinity (AUC0-∞) in participants with mild or moderate HI is similar to that
of healthy control participants.